Publication Name	World Journal of Cardiology
Manuscript ID	101031
Country	Greece

Received	2024-09-02 12:20
Peer-Review Started	2024-09-02 12:20
To Make the First Decision
Return for Revision	2024-09-17 05:58
Revised	2024-09-26 17:43
Second Decision	2024-10-18 01:32
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-10-20 10:22
Articles in Press	2024-10-20 10:22
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-10-28 06:00
Publish the Manuscript Online	2024-10-31 08:01

ISSN	1949-8462 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Cardiac & Cardiovascular Systems
Manuscript Type	Letter to the Editor
Article Title	SGLT2 inhibitors in the prevention of diabetic cardiomyopathy: Targeting the silent threat
Manuscript Source	Unsolicited Manuscript
All Author List	Panayotis K Vlachakis, Panagiotis Theofilis and Dimitris Tousoulis
Funding Agency and Grant Number
Corresponding Author	Dimitris Tousoulis, PhD, Professor, Department of 1st Cardiology, Athens Medical School, National and Kapodistrian University of Athens, Mantouvalou 3, Athens 11527, Greece. drtousoulis@hotmail.com
Key Words	Sodium-dependent glucose transporter 2 inhibitor; Diabetes mellitus; Heart failure; Pathophysiology; Inflammation; Oxidative stress
Core Tip	Sodium-dependent glucose transporter 2 inhibitors show promise in improving cardiac function and reducing cardiovascular risks in patients with type 2 diabetes mellitus and asymptomatic heart failure (HF). Early intervention with these drugs could be key in preventing the progression of diabetic cardiomyopathy, making them an important consideration in managing high-risk diabetic patients before symptoms of HF emerge.
Publish Date	2024-10-31 08:01
Citation	<p>Vlachakis PK, Theofilis P, Tousoulis D. SGLT2 inhibitors in the prevention of diabetic cardiomyopathy: Targeting the silent threat. <i>World J Cardiol</i> 2024; 16(11): 669-672</p>
URL	https://www.wjgnet.com/1949-8462/full/v16/i11/669.htm
DOI	https://dx.doi.org/10.4330/wjc.v16.i11.669

Full Article (PDF)	WJC-16-669-with-cover.pdf
Manuscript File	101031_Auto_Edited_011630.docx
Answering Reviewers	101031-answering-reviewers.pdf
Audio Core Tip	101031-audio.m4a
Conflict-of-Interest Disclosure Form	101031-conflict-of-interest-statement.pdf
Copyright License Agreement	101031-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	101031-non-native-speakers.pdf
Peer-review Report	101031-peer-reviews.pdf
Scientific Misconduct Check	101031-scientific-misconduct-check.png
Scientific Editor Work List	101031-scientific-editor-work-list.pdf
CrossCheck Report	101031-crosscheck-report.pdf